J. B. Chemicals & Pharmaceuticals Limited (BOM:506943)
India
· Delayed Price · Currency is INR 1,703.80
+39.85 (2.39%)
At close: May 20, 2025
BOM:506943 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 39,180 | 34,842 | 31,493 | 24,242 | 20,425 | Upgrade
|
| Revenue Growth (YoY) | 12.45% | 10.63% | 29.91% | 18.69% | 15.09% | Upgrade
|
| Cost of Revenue | 13,166 | 12,142 | 11,963 | 8,655 | 7,227 | Upgrade
|
| Gross Profit | 26,014 | 22,700 | 19,530 | 15,588 | 13,198 | Upgrade
|
| Selling, General & Admin | 6,876 | 8,111 | 7,278 | 5,662 | 4,258 | Upgrade
|
| Other Operating Expenses | 8,820 | 5,661 | 5,190 | 4,460 | 3,358 | Upgrade
|
| Operating Expenses | 17,406 | 15,156 | 13,612 | 10,849 | 8,303 | Upgrade
|
| Operating Income | 8,608 | 7,544 | 5,918 | 4,739 | 4,895 | Upgrade
|
| Interest Expense | -117.3 | -436.52 | -347.68 | -40.85 | -67.43 | Upgrade
|
| Interest & Investment Income | - | 44.26 | 25.39 | 9.39 | 17.79 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 44.07 | -110.87 | -38.01 | 42.34 | Upgrade
|
| Other Non Operating Income (Expenses) | 383.2 | -5.79 | -2.79 | 1.06 | 50.88 | Upgrade
|
| EBT Excluding Unusual Items | 8,874 | 7,190 | 5,482 | 4,671 | 4,939 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 327.43 | 69 | 350.43 | 505.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -2.32 | 0.07 | 24.05 | 524.37 | Upgrade
|
| Other Unusual Items | - | - | 1.28 | 3.98 | - | Upgrade
|
| Pretax Income | 8,874 | 7,515 | 5,552 | 5,049 | 5,969 | Upgrade
|
| Income Tax Expense | 2,278 | 1,989 | 1,452 | 1,189 | 1,484 | Upgrade
|
| Earnings From Continuing Operations | 6,596 | 5,526 | 4,100 | 3,860 | 4,485 | Upgrade
|
| Minority Interest in Earnings | - | - | -1.7 | -6.82 | -5.59 | Upgrade
|
| Net Income | 6,596 | 5,526 | 4,098 | 3,854 | 4,480 | Upgrade
|
| Net Income to Common | 6,596 | 5,526 | 4,098 | 3,854 | 4,480 | Upgrade
|
| Net Income Growth | 19.35% | 34.84% | 6.35% | -13.98% | 64.66% | Upgrade
|
| Shares Outstanding (Basic) | 155 | 155 | 155 | 155 | 155 | Upgrade
|
| Shares Outstanding (Diluted) | 159 | 159 | 157 | 155 | 155 | Upgrade
|
| Shares Change (YoY) | 0.07% | 1.26% | 1.23% | 0.10% | -2.86% | Upgrade
|
| EPS (Basic) | 42.45 | 35.66 | 26.50 | 24.93 | 28.98 | Upgrade
|
| EPS (Diluted) | 41.56 | 34.85 | 26.17 | 24.91 | 28.98 | Upgrade
|
| EPS Growth | 19.25% | 33.17% | 5.06% | -14.04% | 69.50% | Upgrade
|
| Free Cash Flow | 8,049 | 6,629 | 5,562 | 1,073 | 2,670 | Upgrade
|
| Free Cash Flow Per Share | 50.71 | 41.80 | 35.51 | 6.93 | 17.27 | Upgrade
|
| Dividend Per Share | 15.500 | 12.250 | 8.875 | 8.250 | 8.250 | Upgrade
|
| Dividend Growth | 26.53% | 38.03% | 7.58% | - | 50.00% | Upgrade
|
| Gross Margin | 66.40% | 65.15% | 62.01% | 64.30% | 64.62% | Upgrade
|
| Operating Margin | 21.97% | 21.65% | 18.79% | 19.55% | 23.97% | Upgrade
|
| Profit Margin | 16.84% | 15.86% | 13.01% | 15.90% | 21.93% | Upgrade
|
| Free Cash Flow Margin | 20.54% | 19.03% | 17.66% | 4.42% | 13.07% | Upgrade
|
| EBITDA | 10,318 | 8,896 | 7,038 | 5,384 | 5,498 | Upgrade
|
| EBITDA Margin | 26.34% | 25.53% | 22.35% | 22.21% | 26.92% | Upgrade
|
| D&A For EBITDA | 1,710 | 1,352 | 1,120 | 645.45 | 602.84 | Upgrade
|
| EBIT | 8,608 | 7,544 | 5,918 | 4,739 | 4,895 | Upgrade
|
| EBIT Margin | 21.97% | 21.65% | 18.79% | 19.55% | 23.97% | Upgrade
|
| Effective Tax Rate | 25.67% | 26.46% | 26.16% | 23.54% | 24.86% | Upgrade
|
| Revenue as Reported | 39,563 | 35,214 | 31,592 | 24,635 | 21,549 | Upgrade
|
| Advertising Expenses | - | 2,077 | 1,808 | 1,250 | 838.21 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.